The 2025 American Society of Hematology (ASH) Annual Meeting recently concluded in Orlando, USA, showcasing major breakthroughs in lymphoma research and offering new directions for optimizing clinical care. To translate cutting-edge science into clinical insight, Oncology Frontier – Hematology Frontier partners with Professor Qingqing Cai of Sun Yat-sen University Cancer Center to present the “Lymphoma Insights – ASH Special” series, delivering authoritative interpretation of landmark lymphoma studies with practical clinical relevance.

From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held in Tianjin. The meeting brought together leading international and national experts in hematology, focusing on frontier scientific advances and national health priorities, fostering deep academic exchange and shaping future directions of the discipline.

As the new year begins, leading experts gathered in Tianjin. From  January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was successfully held, bringing together top hematology specialists from China and abroad. The conference focused on cutting-edge scientific progress and national health priorities, fostering in-depth discussions on the future of hematology.

From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin. Coinciding with the launch of China’s 15th Five-Year Plan, the conference centered on the theme “Tianjin: Renewing Momentum, Intelligence Leading the Future.” With a forward-looking perspective, the meeting focused on the systemic evolution and ecological integration of hematology, exploring high-quality discipline development pathways and innovative models within the broader “Healthy China” framework.

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the conference, Professor Lei Fan from Jiangsu Provincial People’s Hospital presented a comprehensive overview of the latest advances, current standards, and future directions in first-line treatment for chronic lymphocytic leukemia (CLL), offering valuable guidance for optimizing clinical management.

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Guided by the overarching vision of “Greater Hematology, Greater Public Health, and Greater Health,” CSCO’s hematology committees have built a four-pillar framework centered on standardization, clinical support, collaboration, and prognostic assessment, and a three-core value system emphasizing guideline implementation, resource decentralization, and academic empowerment.

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. As a malignant plasma cell disorder predominantly affecting older adults, multiple myeloma (MM) requires continuous advancement in standardized diagnosis, scientific innovation, and patient-centered management, all of which are critical to the high-quality development of hematologic oncology in China.

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Leading experts and scholars from across China presented advances in both basic and clinical research in leukemia, lymphoma, and myeloma, addressing key challenges in real-world practice and exploring new therapeutic directions.